A151, a cGAS antagonist, is a synthetic oligodeoxynucleotide that abrogates the activation of cytosolic nucleic acid-sensing cGAS and the AIM2 inflammasome by binding to these molecules in a manner that is competitive with immune-stimulatory DNA, which results in attenuation of brain injury in response to ischaemic stroke [17]. The gene discussed is CGAS; the disease is ischemic stroke.